The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 10, 2009
Filed:
Jun. 20, 2006
David Joseph Bartkovitz, Nutley, NJ (US);
Xin-jie Chu, Livingston, NJ (US);
Qingjie Ding, Bridgewater, NJ (US);
Nan Jiang, Fairfield, NJ (US);
Allen John Lovey, North Caldwell, NJ (US);
John Anthony Moliterni, Staten Island, NY (US);
John Guilfoyle Mullin, Jr., Hawthorne, NJ (US);
Binh Thanh VU, North Caldwell, NJ (US);
Peter Michael Wovkulich, Nutley, NJ (US);
David Joseph Bartkovitz, Nutley, NJ (US);
Xin-Jie Chu, Livingston, NJ (US);
Qingjie Ding, Bridgewater, NJ (US);
Nan Jiang, Fairfield, NJ (US);
Allen John Lovey, North Caldwell, NJ (US);
John Anthony Moliterni, Staten Island, NY (US);
John Guilfoyle Mullin, Jr., Hawthorne, NJ (US);
Binh Thanh Vu, North Caldwell, NJ (US);
Peter Michael Wovkulich, Nutley, NJ (US);
Hoffmann-La Roche Inc., Nutley, NJ (US);
Abstract
Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.